REXO4 and breast carcinoma: The downregulation of REXO4 in breast cancer MDA-MB-231 cells resulted in improved sensitivity of temozolomide by increasing the number of apurinic/apyrimidinic sites in the DNA and the enhancement of DNA double strand breaks [55].